Kanazawa University Research: Kanazawa University Invites Industry Collaboration for Cutting-Edge Bio-SPM Research
Why Partner with WPI-NanoLSI?With over 80 leading researchers and access to approximately 60 state-of-the-art Bio-SPM devices, WPI-NanoLSI has delivered significant scientific breakthroughs, including:- Structural analysis of microtubule interiors (Nano Lett., 2025) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/32417/
- Real-time visualization of glutamate receptor molecule dynamics (ACS Nano, 2024) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/31557/
- Observation of influenza virus genome synthesis processes (ACS Nano, 2024) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/31433/
- Study of intrinsically disordered protein structures (Nat. Nanotechnology, 2020) - https://nanolsi.kanazawa-u.ac.jp/en/highlights/19908/
- Live-cell nanoscale imaging (Sci Adv, 2021) – https://nanolsi.kanazawa-u.ac.jp/en/highlights/22249/
For more details on the types of Bio-SPM and their applications, please visit the below link and click 'Overview of each Bio-SPM technology.'https://nanolsi.kanazawa-u.ac.jp/en/research/applications/bio-spm/
Application and Selection ProcessInterested companies can apply for collaborative research by specifying a WPI-NanoLSI researcher of choice or requesting assistance in finding a suitable research partner. Proposals will be evaluated based on their alignment with WPI-NanoLSI's Bio-SPM capabilities and the potential for impactful scientific and industrial advancements.Due to high demand, some applications may not be accepted despite meeting eligibility criteria.For more details on the application process, please visit the below link and click 'Application Guideline (for companies).'https://nanolsi.kanazawa-u.ac.jp/en/research/applications/bio-spm/
ContactResearch Collaboration Office,
WPI-NanoLSI, Kanazawa UniversityEmail : nanolsi_openf01@ml.kanazawa-u.ac.jp
About Kanazawa University and WPI-NanoLSIKanazawa University is a leading research institution dedicated to advancing science and technology on a global scale. The Nano Life Science Institute (WPI-NanoLSI) is at the forefront of nano-life science research, pioneering Bio-SPM technologies to explore biological structures and interactions with unprecedented detail.
Photo: https://mma.prnewswire.com/media/2631664/Kanazawa_University_BioSPMResearch.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/kanazawa-university-research-kanazawa-university-invites-industry-collaboration-for-cutting-edge-bio-spm-research-302389920.html
SOURCE Kanazawa University
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine
ST. PAUL, Minn., Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant. Sidra Medicine's G-Rex® Grant will enable expeditious development, validation, and implementation of a G-Rex® centric CAR-T cell production platform. The G-Rex Grant will allow Sidra Medicine to perform the processes and preclinical development for a CD19 CAR-T cell therapy product that will initially be used in pediatric oncology settings. Sidra Medicine will also receive early access to the G-CART™ process currently in development at Cell Ready, the world's first and only G-Rex centric contract development and manufacturing organization (CDMO). The Grant will also support the implementation of fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs). Lastly, the Grant will support the technology transfer to Sidra Medicine's newly established GMP facility for qualification and implementation. "Sidra Medicine is a pioneering healthcare institution that has innovation weaved into the very core of its precision medicine program. Our GMP facility has been specifically set up to develop better treatment protocols for pediatric diseases including cancers, genetic and rare diseases. The G-Rex® Grant will play a key role in accelerating the readiness of our protocols, particularly for Sidra Medicine's pediatric oncology program. Our preliminary findings have already shown us that the G-Rex® method is outstanding in its simplicity and the unique T cell phenotype resulting from the cell culture. This methodology will allow us to implement an affordable, highly efficient G-Rex based cell manufacturing platform with the most suitable T cell phenotype, ultimately having a positive impact on pediatric patient care and cure," said Sara Deola, M.D., Ph.D., Research Investigator at Sidra Medicine. "We're eager to support the emerging Cell & Gene Therapy (CGT) industry in Qatar and the Middle East. By entering the field of CAR-T without any preconceived manufacturing notions and quickly gathering and reviewing G-Rex manufacturing data, Sidra Medicine quickly recognized the full array of advantages that our G-Rex centric manufacturing process offers relative to alternatives. Sidra Medicine's quick grasp of the technical and economic advantages of G-Rex relative to alternatives gives us confidence that this grant will set the stage for low cost and fully scalable CAR-T manufacturing in Qatar and the Middle East." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & Gene™. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about the G-Rex® Grant Program, please contact info@ For more information about LEAN Cell & Gene™, please use this link to register for the free event series. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialised healthcare or international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333 or visit our website at For more information, follow us on Facebook, Instagram, X and LinkedIn. View original content to download multimedia: SOURCE Bio-Techne Corporation
Hamilton Spectator
4 days ago
- Hamilton Spectator
CNL and Partners Identified Three Canadian Locations to Advance the Design of Renewable Diesel Production Facilities
CHALK RIVER, Ontario, Aug. 01, 2025 (GLOBE NEWSWIRE) — Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology laboratory, in partnership with Expander Energy Inc. (Expander), Fuel Cell Energy (FCE), St Marys Cement (SMC), and Nuclear Promise X (NPX), are pleased to announce that they have identified three Canadian locations as potential sites for the location of renewable diesel production facilities. These facilities would be capable of converting wood waste feedstock into 90 million litres of 'drop-in ready' renewable diesel fuel per year, transforming a waste product into a valuable, low-carbon fuel for the transportation sector. This milestone follows the successful completion of a feasibility study, funded through Natural Resources Canada's (NRCan) Clean Fuels Fund, which demonstrated the economic viability of synthetic diesel production using biomass through water electrolysis. The concept, known as 'e-Syn', encompasses the use of water and water electrolysis as part of an innovative, patented and patent pending process for making bio-synthetic fuels developed by CNL and Expander, called the Biomass Electrolysis to Liquids (BETL™) technology. The project leverages Expander's technology for biomass gasification and bio-synthetic fuel production, and electrolysis technology. The resulting fuel (either bio-synthetic diesel, known as Bio-SynDiesel®, or bio-synthetic aviation fuel, known as Bio-SynJet®) will be comprised entirely of carbon sourced from biogenic (atmospheric) sources, and is expected to have very low life cycle carbon intensity. As part of the feasibility study, a number of potential sites in Canada were evaluated with the intent of selecting one site for a Front-End Engineering Design (FEED) phase of the project. This process culminated in the selection of three locations at sites in British Columbia, Ontario and Quebec, all of which fulfill the necessary requirements in terms of proximity to utilities, and accessibility to major roads and key resources like biomass, among other factors. Following NRCan's approval, the feed study was extended from one to the three sites, a process that is expected to be completed in the Fall of 2025. 'CNL is thrilled at the results that were generated through the feasibility study and is ready to move into the next phase of the project, which has the potential to eventually produce economical, ready-to-deploy, renewable diesel fuel,' commented Stephen Bushby, CNL's Vice-President of Science and Technology. 'As Canada moves towards a net-zero future, synthetic transportation fuels provide an immediate opportunity for the country to reduce its greenhouse gas emissions, with the additional benefit of leveraging waste, such as wood, that may otherwise go to waste. The transportation sector in Canada is responsible for almost 25 per cent of the country's total emissions, so this innovation has the potential to make an important impact toward decarbonizing that sector, as well as Canada's overall carbon footprint.' 'This is not a science experiment – the feasibility study showed that the BETL™ technology can efficiently produce bio-synthetic fuels at prices competitive with existing food competitive Hydrogenation-Derived Renewable Diesel (HDRD) and Hydroprocessed Esters and Fatty Acids (HEFA) fuels,' commented Gord Crawford, Expander's President and CEO. 'Preliminary economic assessments indicated strong financial performance for all three sites. For future opportunities to actually deploy this technology, Expander and CNL plan to install a commercially proven electrolyzer as part of the planned Expander Carseland Alberta Gasifier project in order to technically and commercially derisk potential investment in the three sites under development in the CFF program.' The engineering design work will be based on the utilization of 240 dry tonnes of forestry wood waste per day as feedstock to annually produce approximately 30 million liters of renewable diesel per processing facility by using the BETL™ technology. The design of these facilities could also serve as a template for future sites, both nationally and internationally, using a build, own and operate model. Site specific details will be announced in coordination with local partners, including government and Indigenous nations and organizations, in the near future. The relevance of this project is timely in Canada. While increasing the supply of low-carbon electricity, including nuclear generation and other renewable power options, will be critical to reaching Canada's net zero target, synthetic liquid fuels provide an immediate opportunity to decarbonize marine, aviation and other heavy duty transport sectors using existing engines. These clean fuels are 'drop in' ready, providing an attractive opportunity to decarbonize without the need to make major changes to engine design and manufacturing processes. Converting cellulosic biomass, such as lumber mill and forest residues, to synthetic diesel or sustainable aviation fuel, is also an attractive and promising method to produce fuel that complies with North America's ASTM D975 and Europe's CEN 15940 diesel specifications. Several investors, including major offtakers, have expressed interest in participating in any potential projects. About CNL As Canada's premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services. Guided by an ambitious corporate strategy known as Vision 2030, CNL fulfills three strategic priorities of national importance – restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians. By leveraging the assets owned by AECL, CNL also serves as the nexus between government, the nuclear industry, the broader private sector and the academic community. CNL works in collaboration with these sectors to advance innovative Canadian products and services towards real-world use, including carbon-free energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions. To learn more about CNL, please visit . About Expander Energy Inc. Expander Energy Inc. is a Calgary, Alberta based energy technology company that has developed a patented suite of transportation fuel production technologies to convert biomass and low Carbon Intensity electricity into 'Fossil Free' Low Life Cycle Carbon Intensity synthetic diesel fuel (Bio-SynDiesel®) and synthetic kerosene jet fuel (Bio-SynJet®). Expander's Bio-Energy Carbon Capture and Sequestration (BECCS) solution utilizes cellulosic biomass to produce next generation low CI synthetic fuels while efficiently capturing bio-carbon for geologic sequestration. Bio-SynDiesel®, Bio-SynJet®, BGTL™, EBTL™, BETL™, and CETL™ are trademarks of Expander Energy Inc. To learn more about Expander, please visit . About Nuclear Promise X Nuclear Promise X (NPX) is a forward-thinking Canadian tech start-up, established in 2018, with a mission to transform the nuclear industry through cutting-edge solutions and address the climate crisis. NPX focuses on integrating advanced technology into nuclear plant operations to enhance efficiency, reduce costs, and promote sustainability. To learn more about Nuclear Promise X, please visit . About Fuel Cell Energy Inc. FuelCell Energy, Inc. is a global leader in sustainable energy technologies that address some of the world's most critical challenges around energy, safety, and global urbanization. It collectively holds 531 fuel cell technology patents in the United States and globally. As a leading global manufacturer of proprietary fuel cell technology platforms, FuelCell Energy is uniquely positioned to serve customers including businesses, utilities, governments, and municipalities with sustainable products and solutions. The company's solutions are designed to enable a world empowered by sustainable energy, enhancing the quality of life for people around the globe. Learn more at . About St Marys Cement St Marys Cement is part of Votorantim Cimentos, a global vertically integrated aggregate, cement and concrete solutions provider. With sustainability as a strategic driver, Votorantim Cimentos has committed to ambitious decarbonization goals, including net-zero concrete by 2050 as defined by the GCCA (Global Cement and Concrete Association). As one of its key milestones, the company has set a global 2030 decarbonization target of 475 kg of CO2 per tonne of cement, representing a 24.8% reduction compared to the 2018 baseline year. This target has been approved and verified by the Science Based Target initiative (SBTi). The company works together with industry to reduce emissions and tackle climate change, executing several initiatives simultaneously, including increasing the use of alternative fuels; investing in product innovations with lower clinker content; evaluating carbon capture and utilization technologies; increasing energy efficiency; fostering the circular economy; and participating in the construction of energy-efficient buildings. To learn more about St Marys Cement, please visit: . CNL Contact: Philip Kompass Director, Corporate Communications media@
Yahoo
4 days ago
- Yahoo
Xtalks Announces its Life Science Webinar Calendar for August 2025
Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, healthcare, laboratory technology, medical device, patient recruitment & retention, pharma manufacturing & supply chain and preclinical. TORONTO, Aug. 1, 2025 /PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field! Visit to see our upcoming webinars: CELL AND GENE THERAPYAugust 22 - How Cell-Free mRNA Templates Support Faster Research with High-Quality and Quick Turnaround CLINICAL TRIALSAugust 7 - Improving Clinical Tech Adoption: Site-Centric ApproachesAugust 13 - Accelerating Clinical Research with Master Protocols: Challenges and Benefits to Complex Trial DesignsAugust 14 - Designing Innovative Trials: Navigating Dose Optimization in Oncology CombinationsAugust 15 - AI in Clinical Trials: Early Use Cases and Innovations COMMERCIALIZATION & HEORAugust 19 - 5 Critical Questions to Ask Before Applying AI to Real-World Data DRUG DISCOVERY & DEVELOPMENTAugust 7 - Oral Dosage Innovation for Pediatric Drug DeliveryAugust 7 - Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated PlatformsAugust 12 - Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical TransitionAugust 13 - AI in Drug Discovery & Development: Hype, Reality and What Comes NextAugust 21 - Dose Escalation: Optimizing Cohort Management in Early-Phase DevelopmentAugust 26 - AI in Bioprocessing Today — Accelerate. Predict. Deliver. HEALTHCAREAugust 20 - Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care LABORATORY TECHNOLOGYAugust 6 - Precision Matters: The Critical Role of Accurate Liquid Handling in the Lab MEDICAL DEVICEAugust 25 - Transforming Medical Imaging with AI: Open Tools, Faster Insights PATIENT RECRUITMENT & RETENTIONAugust 20 - Transforming Patient Recruitment: AI and Digital Strategies to Engage the Unreachable 95%August 27 - Enhancing Patient Recruitment in Clinical Research: A Personalized and Engaged Journey PHARMA MANUFACTURING & SUPPLY CHAINAugust 14 - Biofermentation Success Through pH and DO Management PRECLINICALAugust 26 - Advanced In Vivo Efficacy Models for Preclinical Success ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit Contact:Ayesha RashidXtalks ( Tel: +1 (416) 977-6555 x371Email: arashid@ View original content to download multimedia: SOURCE Xtalks Inicia sesión para acceder a tu cartera de valores
